Humana Inc. (HUM) saw its shares surge 5.11% in pre-market trading on Wednesday following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year guidance. The health insurance giant's performance exceeded analyst expectations, demonstrating its ability to navigate the challenging healthcare landscape.
The company reported adjusted earnings per share (EPS) of $6.27 for Q2 2025, surpassing the consensus estimate of $5.92. Revenue for the quarter came in at $32.388 billion, also beating the anticipated $31.894 billion. Notably, Humana's medical cost ratio, a key metric in the insurance industry, stood at 89.7%, aligning with the company's expectations and indicating effective cost management.
In a move that further bolstered investor confidence, Humana raised its full-year 2025 adjusted EPS guidance to approximately $17, up from its previous estimate of $16.25. This revision significantly outpaces the average analyst forecast of $16.38 per share. Additionally, the company increased its full-year revenue guidance to at least $128 billion, up from the previous range of $126 billion to $128 billion. These upward adjustments reflect Humana's optimism about its performance for the remainder of the year and its ability to maintain growth while managing costs effectively in the competitive Medicare Advantage market.
